Point-of-care lipid test market seen reaching $1.17 billion by 2030

The Business Research Company says the global point-of-care lipid test market is growing as cardiovascular disease rates rise and providers look for faster cholesterol testing. The market is expected to rise from $0.74 billion in 2025 to $1.17 billion by 2030, with North America leading now and Asia-Pacific set for the fastest growth.

Why it matters: - Point-of-care lipid testing gives clinicians immediate cholesterol and triglyceride results from a fingerstick blood sample. - Faster results can support earlier cardiovascular risk detection and quicker treatment decisions. - The market is expanding as healthcare systems seek more accessible diagnostic tools for heart-health monitoring.

What happened: - The Business Research Company released a report on the point-of-care lipid test market on August 24, 2026. - The report pegs the market at $0.74 billion in 2025 and expects it to reach $0.82 billion in 2026. - The market is forecast to reach $1.17 billion by 2030. - The company projects a 9.7% CAGR from 2025 to 2026 and a 9.4% CAGR through 2030. - Download a free sample of the report. - View the full market report.

The details: - Point-of-care lipid tests use a simple fingerstick blood sample to measure cholesterol and triglyceride levels. - Traditional lipid testing relies on laboratory analysis and does not deliver immediate results. - The report identifies rising cardiovascular disease rates as a major growth driver. - The report also points to biosensor advances, greater cholesterol-awareness, and the convenience of point-of-care devices. - Cardiovascular disease includes coronary artery disease, stroke and hypertension. - Sedentary lifestyles and lower physical activity are contributing to obesity and related risk factors. - The American Heart Association reported in January 2024 that US cardiovascular disease deaths reached 931,578, up from 928,741 the year before. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - Demand is shifting toward faster, portable testing that can move beyond centralized labs. - Integration with mobile apps and cloud platforms could make lipid monitoring more continuous and easier to track over time. - Wider use in home healthcare suggests testing is moving closer to the patient, not just the clinic. - Multi-analyte devices and rapid cardiovascular risk assessments signal a broader push toward compact, multi-use diagnostic tools.

What's next: - Growth is expected to be supported by more adoption in clinics, hospitals and home healthcare settings. - The report says fingerstick testing, portable analyzers and home-based monitoring will be key trends. - Strategic partnerships between device makers and software developers may shape product development. - The company’s 2026 reports will add market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards and updated graphics.